DMA Diamedica Therapeutics

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN
THE UNITED STATES 


DiaMedica Inc. (TSX VENTURE:DMA), is pleased to announce that it has completed
and closed a non-brokered private placement of 154,500 Units at a price of $0.90
per unit for aggregate gross proceeds of approximately $139,000 (the
"Offering"). Each Unit will consist of one common share in the capital stock of
DiaMedica (a "Common Share") and one half of one common share purchase warrant
(each whole warrant, a "Warrant"). Each Warrant will entitle the holder thereof
to purchase one additional Common Share for the price of $1.10 prior to December
23, 2015, subject to an acceleration of the expiry date of such Warrants in
certain circumstances. A finder's fee equal to 6% cash and 6% warrants of the
aggregate gross proceeds raised under the Offering may be payable to persons
arm's length to DiaMedica at its discretion in connection with introducing
subscribers to the Offering.


DiaMedica intends to use the net proceeds from the Offering for research and
development, including a Phase II clinical trial for Type 2 diabetes, and for
working capital and general and administrative purposes.


The common shares issued pursuant to the Private Placement are subject to a
statutory hold period which expires on May 4, 2014. The Offering remains subject
to certain conditions including approval of the TSX Venture Exchange.


About DiaMedica

DiaMedica Inc. (TSX VENTURE:DMA) is a biotechnology company developing
first-in-class treatments for the treatment of diabetes. DiaMedica's lead
compound, DM199, is a recombinant human protein for the treatment of both Type 1
and Type 2 diabetes and their complications. The Company is also developing the
first therapeutic GPCR agonist monoclonal antibody, DM204, for the treatment of
Type 2 diabetes and cardiovascular disease. DiaMedica's shares trade on the TSX
Venture Exchange (TSX VENTURE:DMA). For more information please visit
www.diamedica.com.


FORWARD-LOOKING STATEMENTS

The statements made in this press release that are not historical facts contain
forward- looking information that involves risk and uncertainties. All
statements, other than statements of historical facts, which address DiaMedica's
expectations, should be considered forward-looking statements. Such statements
are based on management's exercise of business judgment as well as assumptions
made by and information currently available to management. When used in this
document, the words "may", "will", "anticipate", "believe", "estimate",
"expect", "intend" and words of similar import, are intended to identify any
forward-looking statements. You should not place undue reliance on these
forward-looking statements. These statements reflect a current view of future
events and are subject to certain risks and uncertainties as contained in the
Company's filings with Canadian securities regulatory authorities. Should one or
more of these risks or uncertainties materialize, or should underlying
assumptions prove incorrect, actual results could differ materially from those
anticipated in these forward- looking statements. The Company undertakes no
obligation, and does not intend, to update, revise or otherwise publicly release
any revisions to these forward-looking statements to reflect events or
circumstances after the date hereof, or to reflect the occurrence of any
unanticipated events. Although management believes that expectations are based
on reasonable assumptions, no assurance can be given that these expectations
will materialize.


Neither the TSX Venture Exchange nor its Regulation Services Provider (as that
term is defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of the contents of this News
Release.


FOR FURTHER INFORMATION PLEASE CONTACT: 
DiaMedica
Rick Pauls
President and CEO
763-710-4455
info@diamedica.com

DiaMedica Inc. (TSXV:DMA)
Historical Stock Chart
From Jun 2024 to Jul 2024

DiaMedica Inc. (TSXV:DMA)
Historical Stock Chart
From Jul 2023 to Jul 2024